Evidence map›Paper›PMID 36319886›Full record

ReviewPharmaceutical research2023

Enhancing the Cellular Production of Extracellular Vesicles for Developing Therapeutic Applications.

Nina Erwin, Maria Fernanda Serafim, Mei He

Abstract readReview
In one paragraph

Review in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Impact ofMicroorganisms · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nina ErwinDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, 32610, USA.
Maria Fernanda SerafimDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, 32610, USA.
Mei HeDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, 32610, USA. mhe@cop.ufl.edu.ORCID http://orcid.org/0000-0001-5316-9326

Funding

Equipment Supplement to R35GM133794R35GM133794 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Mei He · 2019 to 2026
$2.9M
NIGMS NIH HHS 1R35GM133794NIGMS NIH HHS R35 GM133794
6 · The paper itself

Abstract

Extracellular vesicles (EVs) have various advantageous properties, including a small size, high biocompatibility, efficient cargo loading, and precise cell targeting ability, making them promising tools for therapeutic development. EVs have been increasingly explored for applications like drug delivery. However, due to limited cellular secretion rates of EVs, wide-scale clinical applications are not achievable. Therefore, substantial strategies and research efforts have been devoted to increasing cellular secretion rates of EVs. This review describes various studies exploring different methods to increase the cellular production of EVs, including the application of electrical stimulus, pharmacologic agents, electromagnetic waves, sound waves, shear stress, cell starvation, alcohol, pH, heat, and genetic manipulation. These methods have shown success in increasing EV production, but careful consideration must be given as many of these strategies may alter EV properties and functionalities, and the exact mechanisms causing the increase in cellular production of EVs is generally unknown. Additionally, the methods' effectiveness in increasing EV secretion may diverge with different cell lines and conditions. Further advancements to enhance EV biogenesis secretion for therapeutic development is still a significant need in the field.

Indexed as

Extracellular VesiclesCell LineDrug Delivery SystemsProtein Transportbiogenesisexosomesextracellular vesiclesmolecular engineeringsecretion

Identifiers

PMID36319886
PMCPMC10321241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.